DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0709-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
Recall history in this database
Classification mix: Class II: 5.
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) unit dose recall — FDA D-0711-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 10 Tablets (10 x 1) unit dose recall — FDA D-0710-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0707-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
DrugJul 29, 2026
Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 10 Tablets (10 x 1) unit dose blisters recall — FDA D-0708-2026
Subpotent Drug
Class IIFDA: OngoingMajor Pharmaceuticals
Understanding this recall history
This page summarizes recall records in which the official source identifies Major Pharmaceuticals as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.